What is Exploramed?
Exploramed operates as a specialized medical device incubator, functioning as a catalyst for innovation by identifying and addressing persistent clinical inefficiencies. The company distinguishes itself through a patient-driven development philosophy, prioritizing cost-effective solutions that enhance quality of life. With a proven track record of launching eight distinct entities across four funding cycles, Exploramed serves as a bridge between conceptual medical research and commercial-grade technology. Its market position is defined by a collaborative approach, partnering with industry leaders to challenge conventional medical paradigms and deliver high-impact, scalable solutions that meet the rigorous demands of modern healthcare systems.
How much funding has Exploramed raised?
Exploramed has raised a total of $47.5M across 3 funding rounds:
Private Equity
$18.5M
Private Equity
$14M
Private Equity
$15M
Private Equity (2008): $18.5M with participation from Morgenthaler Partners and NEA
Private Equity (2014): $14M led by New Enterprise Associates
Private Equity (2015): $15M supported by NEA
Key Investors in Exploramed
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Morgenthaler Partners
Morgenthaler is a premier venture capital and private equity firm with over 40 years of experience, specializing in investments within the Information Technology and Life Sciences sectors.
NEA
A prominent venture capital firm providing sustained financial backing to high-growth companies across the technology and healthcare landscapes.
What's next for Exploramed?
Looking ahead, Exploramed is poised to leverage its recent capital injection to accelerate the development of its current pipeline and potentially expand its incubation footprint. The firm's strategic focus remains on refining its internal processes to shorten the time-to-market for its portfolio companies. By continuing to align with top-tier venture partners, Exploramed is well-positioned to navigate the regulatory and commercial complexities inherent in the life sciences industry. Future growth will likely center on deepening its technological capabilities and exploring new therapeutic areas where patient-driven innovation can yield the most significant clinical and economic outcomes.
See full Exploramed company page
